Baylor College of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Baylor College of Medicine sits in the top decile of US sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count).

616 total trials 93 currently recruiting 376 completed early-phase tilt top decile by trial count

Baylor College of Medicine: 616 sponsored US clinical trials, 93 recruiting.

Baylor College of Medicine sponsors 616 registered US clinical trials on ClinicalTrials.gov, 93 of them currently recruiting, and 376 completed. 59 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 7 trials.

Top-decile sponsor footprint

Baylor College of Medicine ranks in the top decile of sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

376 of 452 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

616 total, page 11 of 13

COMPLETED

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

NCT00717223

COMPLETED Phase 2

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

NCT00539695

TERMINATED Phase 1

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

NCT00579111

COMPLETED Phase 2

Folate Rechallenge

NCT00672360

COMPLETED

Screening for Bladder Cancer

NCT00848627

COMPLETED Phase 2

Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma

NCT00578864

COMPLETED Phase 4

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

NCT00988364

COMPLETED Phase 1

Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)

NCT00586560

COMPLETED Phase 4

Ziprasidone in Pediatric Bipolar Disorder

NCT00622739

COMPLETED

Parental Feeding Styles and Child Dietary Quality

NCT03390621

COMPLETED NA

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

NCT00529841

COMPLETED Phase 4

Selegiline to Zelapar Switch Study in Parkinson Disease Patients

NCT00640159

TERMINATED NA

Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain

NCT00425230

COMPLETED Phase 1

Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells

NCT00458679

COMPLETED NA

Time to Defibrillation Using Automated External Defibrillators by Pediatric Residents in Simulated Cardiac Arrests

NCT00640354

COMPLETED Phase 4

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003

COMPLETED

Prevalence of Hypogonadism in Male Cancer Patients

NCT00472940

COMPLETED Phase 3

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

NCT00435370

COMPLETED Phase 4

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

NCT00590122

COMPLETED Phase 2

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

NCT00383786

COMPLETED Phase 1

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240

TERMINATED Phase 1

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma

NCT00383097

COMPLETED Phase 1

Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer

NCT00403221

COMPLETED

The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).

NCT00361946

COMPLETED Phase 1

Assessment of GVG for the Treatment of Methamphetamine Dependence

NCT00506935

COMPLETED Phase 4

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

NCT00340613

COMPLETED Early Phase 1

Pregabalin in the Treatment of Essential Tremor

NCT00646451

TERMINATED Phase 1

Treatment of Subarachnoid Hemorrhage With Human Albumin

NCT01747408

COMPLETED NA

Watchful Waiting of Incisional Hernias

NCT00351455

COMPLETED Phase 1

A Study of the Relationship Between Disulfiram and Cocaine Self-administration.

NCT00729300

COMPLETED Phase 4

Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease

NCT00646204

COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

NCT00616291

COMPLETED NA

Collaborative Care for Heart Failure Patients With the Metabolic Syndrome

NCT00293852

COMPLETED Phase 4

Continuous Subcutaneous Infusion of Pramlintide and Insulin

NCT00291772

TERMINATED NA

Treatment of Subarachnoid Hemorrhage With Human Albumin

NCT00283400

TERMINATED Phase 3

Steroid Treatment for Sickle Cell Pain Crisis

NCT00263562

COMPLETED Phase 1

Phase 1 Intrathecal Topotecan for Neoplastic Meningitis

NCT00674674

COMPLETED Phase 4

Dexmedetomidine in Pediatric Tonsillectomy

NCT01057381

COMPLETED Phase 1

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

NCT00120081

COMPLETED Phase 1

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

NCT00206388

COMPLETED NA

Effect of Curcumin on Lung Inflammation

NCT01514266

COMPLETED Phase 2

Pharmacogenetics of Disulfiram for Cocaine

NCT00149630

COMPLETED Phase 4

Lantus in the Treatment of Type 1 Diabetes Children

NCT00206401

TERMINATED Phase 4

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266

COMPLETED NA

Physician Uncertainty Reduction for Hypertension

NCT00201084

COMPLETED

Ability to Cope With Type 1 Diabetes

NCT00206362

COMPLETED Phase 4

Novel Treatment for Diastolic Heart Failure in Women

NCT00206232

COMPLETED

Sleep, HIV Disease Progression, and Function in HIV Infected Children and Adolescents

NCT00253695

COMPLETED

Ability to Cope With Type 1 Diabetes

NCT00206349

COMPLETED Phase 1

Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant

NCT00078533

← Previous Page 11 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 173
Phase 2 59
Phase 3 13
Phase 4 46

What is open in the Baylor College of Medicine pipeline

93 recruiting of 616 indexed (15% open); 376 completed (61%).

Phase mix: 59 late (III/IV) vs 232 early (I/II) (early-phase heavy).

Top condition: Non-Hodgkin Lymphoma (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Baylor College of Medicine: open-pipeline peers nationwide

Peers matched on 616 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 0%5%10%15%20% Total trials Recruiting share Baylor College of MedicineUniversity of Southern CaliforniaUS Department of Veterans AffairsUniversity of RochesterJanssen Research & DevelopmentStanford UniversityBaylor UniversityCornell University59th Medical Wing
Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 616 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Baylor College of Medicine page

616 registered trials is a research-attention snapshot, not an endorsement of Baylor College of Medicine or any single study.

  • 93 of Baylor College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Hodgkin Lymphoma is the condition Baylor College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Baylor College of Medicine pipeline card: 616 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.